XML 27 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2019

Accounting Policies [Abstract]

Schedule of Disaggregation of Revenue

In the following table, revenue is disaggregated by primary geographical market, major product line, and timing of revenue recognition.

In thousands of US dollars ($)		Three Months Ended June 30,								Six Months Ended June 30,
Primary geographical markets		2019				2018				2019				2018
North America			368				351				592				716
Europe			54				64				94				219
Asia			97				224				343				315
			519				639				1,029				1,250

		Three Months Ended June 30,								Six Months Ended June 30,
Major products/services lines		2019				2018				2019				2018
Hardware			212				397				352				817
Grants			0				20				0				45
Consumables			91				64				153				139
Contract research services			111				67				349				67
Sample preparation accessories			35				47				35				96
Technical support/extended service contracts			28				22				67				50
Shipping and handling			14				16				19				28
Other			28				6				54				8
			519				639				1,029				1,250

		Three Months Ended June 30,								Six Months Ended June 30,
Timing of revenue recognition		2019				2018				2019				2018
Products transferred at a point in time			506				609				1,007				1,185
Products and services transferred over time			13				30				22				65
			519				639				1,029				1,250

Schedule of Contract Balances

Contract balances

In thousands of US dollars ($)		June 30, 2019				December 31, 2018
Receivables, which are included in ‘Accounts Receivable’			411				475
Contract liabilities (deferred revenue)			58				58

Schedule of Future Related to Performance Obligations

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.

In thousands of US dollars ($)		2019				2020				2021				Total
Extended warranty service			26				32				-				58

Schedule of Customer Concentration Risk Percentage

The following table illustrates the level of concentration as a percentage of total revenues during the three months and six months ended June 30, 2019 and 2018.

		For the Three Months Ended
		June 30,
		2019				2018
Top Five Customers			47	%			54	%
Federal Agencies			9	%			12	%

		For the Six Months Ended
		June 30,
		2019				2018
Top Five Customers			55	%			38	%
Federal Agencies			14	%			8	%

The following table illustrates the level of concentration as a percentage of net accounts receivable balance as of June 30, 2019 and December 31, 2018. The Top Five Customers category may include federal agency receivable balances if applicable.

		June 30, 2019				December, 31, 2018
Top Five Customers			60	%			54	%
Federal Agencies			5	%			5	%

Schedule of Computation of Loss Per Share

The following table illustrates our computation of loss per share for the three months and six months ended June 30, 2019 and 2018:

		For the Three Months Ended								For the Six Months Ended
		June 30,								June 30,
		2019				2018				2019				2018
Numerator:
Net loss		$	(2,766,842	)		$	(2,281,232	)		$	(4,822,015	)		$	(4,512,886	)
Deemed dividend on down round feature			-				(213,012	)			-				(213,012	)
Deemed dividend on beneficial conversion feature			(889,532	)			(10,532,291	)			(1,949,731	)			(10,532,291	)
Preferred stock dividends			(420,489	)			(95,879	)			(776,098	)			(95,879	)
Net loss applicable to common shareholders		$	(4,076,863	)		$	(13,122,414	)		$	(7,547,844	)		$	(15,354,068	)

Denominator for basic and diluted loss per share:
Weighted average common stock shares outstanding			1,837,913				1,426,698				1,780,881				1,395,187

Loss per common share – basic and diluted		$	(2.22	)		$	(9.20	)		$	(4.24	)		$	(11.01	)

Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share

The following table presents securities that could potentially dilute basic loss per share in the future. For all periods presented, the potentially dilutive securities were not included in the computation of diluted loss per share because these securities would have been anti-dilutive to our net loss. The Series D Convertible Preferred Stock, Series G Convertible Preferred Stock, Series H Convertible Preferred Stock, Series H2 Convertible Preferred Stock, Series J Convertible Preferred Stock, Series K Convertible Preferred Stock and Series AA Convertible Preferred Stock are presented below as if they were converted into shares of common stock according to the conversion terms.

		As of June 30,
		2019				2018
Stock options			347,070				244,467
Convertible debt			692,715				346,133
Common stock warrants			8,880,554				6,263,607
Convertible preferred stock:
Series D Convertible Preferred Stock			25,000				25,000
Series G Convertible Preferred Stock			26,857				26,857
Series H Convertible Preferred Stock			33,334				33,334
Series H2 Convertible Preferred Stock			70,000				70,000
Series J Convertible Preferred Stock			115,267				115,267
Series K Convertible Preferred Stock			229,334				229,334
Series AA Convertible Preferred Stock			7,518,622				5,195,400
			17,938,753				12,549,399

Schedule of Stock Based Compensation Expense

The following table summarizes the effect of this stock-based compensation expense within each of the line items of our costs and expenses within our Consolidated Statements of Operations:

		For the Three Months Ended								For the Six Months Ended
		June 30,								June 30,
		2019				2018				2019				2018
Cost of sales		$	12,082			$	-			$	20,398			$	-
Research and development			49,948				15,649				84,573				31,148
Selling and marketing			28,959				7,279				51,078				14,476
General and administrative			271,193				39,321				451,525				102,646
Total stock-based compensation expense		$	362,182			$	62,249			$	607,574			$	148,270

Schedule of Assets and Liabilities Measured at Fair Value on Recurring Basis

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2019:

						Fair value measurements at June 30, 2019 using:
		June 30, 2019				Quoted prices in active markets (Level 1)				Significant other observable inputs (Level 2)				Significant unobservable inputs (Level 3)
Equity Securities			16,643				16,643				-				-
Total Financial Assets		$	16,643			$	16,643			$	-			$	-

The following tables set forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of December 31, 2018:

						Fair value measurements at December 31, 2018 using:
		December 31, 2018				Quoted prices in active markets (Level 1)				Significant other observable inputs (Level 2)				Significant unobservable inputs (Level 3)
Equity Securities			16,643				16,643				-				-
Total Financial Assets		$	16,643			$	16,643			$	-			$	-

Tabular disclosure of all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. The disclosure concerning concentrations of risk may consist of the following information: (1) for concentrations of credit risk disclosure may include: (a) information about the (shared) activity, region, or economic characteristic that identifies the concentration, (b) the maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity, (c) the policy of requiring collateral or other security to support financial instruments subject to credit risk, information about the entity's access to that collateral or other security, and the nature and a brief description of the collateral or other security supporting those financial instruments, and (d) the policy of entering into master netting arrangements to mitigate the credit risk of financial instruments, information about the arrangements for which the entity is a party, and a brief description of the terms of those arrangements, including the extent to which they would reduce the entity's maximum amount of loss due to credit risk and (2) for disclosure of quantitative information about the market risks of financial instruments that is consistent with the way the company manages or adjusts those risks, disclosure may include: (a) more details about current positions and perhaps activity during the period, (b) the hypothetical effects on comprehensive income (or net assets), or annual income, of several possible changes in market prices, (c) a gap analysis of interest rate re-pricing or maturity dates, (d) the duration of the financial instruments, (e) the entity's value at risk from derivatives and from other positions at the end of the reporting period and the average value at risk during the year, or (f) other ways of reporting quantitative information as internally developed.

+ References + Details